Prevalence of Potential Drug-Drug Interactions in an Intensive Care Unit at a Brazilian Hospital

被引:0
作者
Cruciol-Souza, Joice M. [1 ]
Ferreira-Filho, Olavo F. [2 ]
Obreli-Neto, Paulo R. [3 ]
机构
[1] Univ Estadual Londrina, Dept Ciencias Farmaceut, Londrina, Parana, Brazil
[2] Univ Estadual Londrina, Dept Clin Med, Londrina, Parana, Brazil
[3] Univ Estadual Maringa, Dept Farmacol & Terapeut, Maringa, Parana, Brazil
来源
LATIN AMERICAN JOURNAL OF PHARMACY | 2012年 / 31卷 / 10期
关键词
Cross-sectional study; Developing countries; Drug-drug interactions; Intensive care unit; Pharmacoepidemiology; EVENTS;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The present study investigated the prevalence and characteristics of potential drug-drug interactions (DDIs) in prescriptions for inpatients in an intensive care unit (ICU) at a Brazilian hospital. The data were retrieved from the handwritten prescription and medical records of inpatients during hospitalization in the ICU between August 2007 and November 2007. The data were obtained during the first 24 h of hospitalization. Potential DDIs were identified using the Micromedex system. Inpatient, drug, and DDI characteristics were described. Of the 147 patients who were admitted to the ICU during the period of study, 79 (53.7 %) were male. The average age of all of the inpatients was 59.7 +/- 18.7 years. Potential DDIs were identified in 79 (53.7 %) inpatients. Most of them (31; 21 %) had major DDIs. The most common major DDI in this sample was fentanyl + rnidazolam in eight inpatients (5.4 %). More studies on the pharmacoepidemiology of DDIs and their clinical impact can contribute to pharmacist insertion into the clinical team in Brazil.
引用
收藏
页码:1469 / 1475
页数:7
相关论文
共 29 条
[1]  
Abarca Jacob, 2004, J Am Pharm Assoc (2003), V44, P136, DOI 10.1331/154434504773062582
[2]  
[Anonymous], WHO AN THER CHEM CLA
[3]   FREQUENT HYPOXEMIA AND APNEA AFTER SEDATION WITH MIDAZOLAM AND FENTANYL [J].
BAILEY, PL ;
PACE, NL ;
ASHBURN, MA ;
MOLL, JWB ;
EAST, KA ;
STANLEY, TH .
ANESTHESIOLOGY, 1990, 73 (05) :826-830
[4]   Pharmacokinetic changes in critical illness [J].
Boucher, Bradley A. ;
Wood, G. Christopher ;
Swanson, Joseph M. .
CRITICAL CARE CLINICS, 2006, 22 (02) :255-+
[5]   Predicting the Clinical Relevance of Drug Interactions From Pre-Approval Studies [J].
Caccia, Silvio ;
Garattini, Silvio ;
Pasina, Luca ;
Nobili, Alessandro .
DRUG SAFETY, 2009, 32 (11) :1017-1039
[6]  
Cadwallader D.E, 1985, BIOPHARMACEUTICS DRU
[7]   Treatment of anxiety and depression in transplant patients - Pharmacokinetic considerations [J].
Crone, CC ;
Gabriel, GM .
CLINICAL PHARMACOKINETICS, 2004, 43 (06) :361-394
[8]  
Cruciol-Souza JM, 2006, J PHARM PHARM SCI, V9, P427
[9]   Preventable adverse drug events in hospitalized patients: A comparative study of intensive care and general care units [J].
Cullen, DJ ;
Sweitzer, BJ ;
Bates, DW ;
Burdick, E ;
Edmondson, A ;
Leape, LL .
CRITICAL CARE MEDICINE, 1997, 25 (08) :1289-1297
[10]   Drug dosing in critically ill patients with renal failure: A pharmacokinetic approach [J].
DeBellis, RJ ;
Smith, BS ;
Cawley, PA ;
Burniske, GM .
JOURNAL OF INTENSIVE CARE MEDICINE, 2000, 15 (06) :273-313